Novartis
Search results
Four-plex test for SARS-CoV-2, Influenza A/B and RSV receives FDA Emergency Use Authorization. Now, HCPs will be able to detect and differentiate these respiratory viruses within a single patient visit, enabling improved public health outcomes.
Roche Diagnostics develops innovative products and services that address the prevention, diagnosis, monitoring, screening and treatment of diseases.
More than 800,000 documents available on demand for Centralized Diagnostics, Tissue Diagnostics, Molecular Diagnostics, Life Science, Sequencing and Custom Biotech product information.
We combine science, data and insights to transform the way diseases can be prevented, diagnosed and monitored. Our medical assays, digital solutions and services help people live healthier lives.
Roche Diagnostics develops and produces medical tests and digital tools that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
For healthcare providers, we offer virtual care and decision support solutions to confidently diagnose, optimise resources and help personalise treatment. For patients, we offer digital diagnostic solutions for self-monitoring and the delivery of test results.
Roche Diagnostics is the diagnostic division of F. Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications. Learn how in vitro diagnostics are an integral part of decision-making along the entire continuum of a patient’s health or disease.
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States. Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwide.
When the pandemic hit, we responded swiftly by creating a high-quality PCR SARS-CoV-2 test in just 42 days, the first commercial EUA granted by the FDA. As COVID-19 progressed, we expanded our diagnostic portfolio and developed 13 tests and solutions within 12 months.
At Roche Diagnostics, we develop diagnostic tests, instruments and digital solutions with the power to transform healthcare for people around the globe.
